{"ticker": {"uuid": "98cade41-fe6f-4f1c-8211-b2e42cd2c12c", "symbol": "VRXA", "name": "Veraxa Biotech AG Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/why-veraxa-biotech-vrxa-could-184016312.html", "source_name": "NewMediaWire", "published_at": "2026-07-15T18:40:16+00:00", "published_display": "15 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-vrxa-partners-ardigen-193000265.html", "source_name": "NewMediaWire", "published_at": "2026-07-13T19:30:00+00:00", "published_display": "13 Jul 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC\u00ae Pipeline", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-launch-ai-enabled-110000224.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI partnership aims to sharpen cancer target selection at VERAXA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVnl4ZzZGN3BtUXVxQlJ5a3ZDalg5c3FVWkQzc0U5MUpIcjRrMk1WVlE3eWI1MTctRDhnSnZ4WGxHS1dZeFo1NHp3dUFOOGV1c3ViSlBLWE9NR01tQ1hDVzVBc09zdkt2VzYtQjBOLWxLeXdaUE9wRnZTcnlRQVBsUTkwNHFxaTVhZ3hUNl81NXNmRTlLTVpueWF0LWtzdmJsQXNkM3B0TkJDYWctTkFfRFVtaUkxWGN0c0hF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech AG Appoints Carl von Halem as Interim\u00a0Chief Financial Officer and Successor to Torsten B\u00fcrgermeister", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-ag-appoints-carl-200500695.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T20:05:00+00:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Advances Lead BiTAC(R) T-Cell Engager Program With Cell Line Development Partnership", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-vrxa-advances-lead-183000631.html", "source_name": "NewMediaWire", "published_at": "2026-07-09T18:30:00+00:00", "published_display": "09 Jul 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRXA Price History for Veraxa Biotech Ag Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1ZaFN4bTZVd3phOGZwUUMwTUNNeWF5SVFpSlpDU3ozRlFvbVBrazJqT2FmaGgxQ2RzVWtlR0h2a0ZpVW00R2ZFUlpMM1ZGcnFSSFphSWZibUV6QV81X3hZT2hKZEh0SlFk?oc=5", "source_name": "Barchart.com", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9uMEF3NUMtNlltZ1gxR2xuMWZyMGRZYnpib3Q1NWo4VjFZMmM0WC1UVm9pWTNGSzJxNW12enVWSjFWR2FNU3pNRTM1RnNpQy1j?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T03:14:35+00:00", "published_display": "07 Jul 2026 03:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-vrxa-highlights-bitac-190000080.html", "source_name": "NewMediaWire", "published_at": "2026-07-06T19:00:00+00:00", "published_display": "06 Jul 2026 19:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxQbDhyTWhiZXZiVnVsd1FKM3dkU245MktZOHpwUFNCamRwQUtXQjlvSHNnbHh6MHFhSjZLdFdHWE1pVUo3Qm1XQlVjQ1hURy1kZHViR2I1bTBDWlE3dmJvcVZaSnA0QXp3TmFXQ19zck04V2pneFdzZlBScm93R2p5X3M4cTNvWnNpZ3RtMU5xSDhGd1NkUVloNFVCcFhkcjJVdFV0ZzZnc0R4UVROZHFmcmxESmhRX2g1V2t3azFMVXRjWXYtNFQxZno1SzFtRE1LRktjdTc0VEZzSFNqM2xGOC1CeEJNVFNxcmZNNVhQVXMtWUVPcW90enFfYldPbEhfb0pEWHdaVVptN2lVY0NtVjQ0bHhfcm9K?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-06T16:13:27+00:00", "published_display": "06 Jul 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Cancer Therapy Strategy VERAXA Is Betting the Company On", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cancer-therapy-strategy-veraxa-betting-160053349.html", "source_name": "Exec Edge", "published_at": "2026-07-06T16:00:53+00:00", "published_display": "06 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech Provides Business Update and Further Details on\u00a0Partnering Strategy and Development Timelines", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-provides-business-further-110000337.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T11:00:00+00:00", "published_display": "06 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA says its BiTAC cancer pipeline is drawing partner interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQRXc1WlFyekVveDdKSEhFNl96QlBUWnRxWlV5YlY0bHU4MGRPNXZuTUdJc1IzSGNXQ2QzdmhtM1VDQmFrWGJ6VEUtWjRyenI1c3FYN0kySzZSX1Y1V2pseGQyUmt0Zzg3YjhFdTVHY1VfNTljd3JZbUZGZXFVX0YxbE9nVkhmMXZYZURsc2ZsSmEwX2dNOUdEYmlpemNLS1I5TzlEaThPZUVnVk1sUlJKczRwZTFLbDFP?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veraxa Biotech Holding (VRXA) Stock Analysis Report | Financials & Insights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBSQi15YkhYZFNXOXN2RV9KMzVraFkyOTZTSlVudmJPa01OX25BTVNqVEpSdnlmTjNVT3RaRzNEU0w2SXd6b2lnT011M2JTNHJnMFhF?oc=5", "source_name": "Benzinga Espa\u00f1a", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-vrxa-initiates-cell-193000059.html", "source_name": "NewMediaWire", "published_at": "2026-07-02T19:30:00+00:00", "published_display": "02 Jul 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOOTRONFI2QTZxVGRlbHRmeUpPUk0wY1k3U19iWmhwbm1vTC1hQkdTaTd0Rk1GdTZMZ1VkZVFEMDktWEQ5LUJNQk1vVXkzT1hoUG1VUEppMks1ZklGY3RPVWlmbUZoTjNLUFJ1T0VqbTVvbHlsZVdCY0gxRmhEOTFZS3pWX2dIeXZ1UGJFazNjWTU3Smk3LW5j?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA advances lead cancer drug toward manufacturing work with ATUM", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPaVlOeWFkVVVoRmxYdjk2LVJEUHA0eHRuM1VoWkFEaUFQTmdjek5DRXJUbTdiVzZjU01fWC1OdHZNZEhycUJfdFpTNng5SzdBcXp5bkRSYXczU0R4bFJubWhpbWRrMFQwSmZYM3g4aUtHOFdCV1YtSXZtSkREdzRLNmEweElaampFM1RmQWt2b0RiR3EzYzd2cEpjSnFiZXFVT19zempvRzFRMmcxOV9tVGJ1dklNZVd3cGFYNlBYVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA adds 60% more lab space in Heidelberg for cancer drug work", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcE9rckFtZE96T3VsU1JEcEk5bHVyWWhpa0tFcVZVbi0wODZDdExMWm5wS0FZVEFuMUpRUzYwWWJhNXpLNkQ5QURIVGlxc3NLaGRScWMxZGVpeHNqSmlhLXdqU1RvZV91N0ZDUmFYWWxId09lYW1WUnc0V3AzTnI2TzNmbzlMUzZ6aXhTOWNLZk5MTko3MUtma2VQWU5Ec0FDNl9ib1U2U1ppUzdLNjJ4LU1XVlJyLS1saVN5VTNNaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOSFVUR1lwVFdDbkhnT1M3RnZlSUcwUzA1T0kyUldmTThDZVlmUlV0NVExLXpHM3IwVUV3eHZGSnB0bk9pNkxyTl9HSThOdl9uMF9nYzh3RU1Pb2xHYW9IeDQ2bFRqVnJuTE9IREZuMVFFeGlseGJTcGtJR1FOTVp0VldRZ3NyTVdMWFhqQ0g1bEZyUlVLbkZjWDdzeFpnX3hsRkFDQTRKN3FvUmVhdTN2UjBURjUxRDJFZzhqN2sxcjVCMEdKcUg2cUtIaWxWZEwwbHVKLWhEN3k?oc=5", "source_name": "Barchart.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRXA SEC Filings - Veraxa Biotech AG 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE10UnllaUM0VzdKQVRCWmRja3hKTjRtaGdkRHlJT0MtdlpQSE5WVU9CVVRVcldpbUZmVVhBZ0RwZ3VkOFM3UGtRX2RvX2RrZFN4aXViQ2xNUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veraxa Biotech Stock: Post-Merger Valuation Does Not Match The Risk (NASDAQ:VRXA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOUzdVbFdoUWtGZkNMMFgtRlZ2VDJIZWdaMEd0WjZ1V0xJMUxUd0ZFRmNEQkt2SVh3RkgxQ2NGTHFKNUtKTFlfYk9aYXJLbDdWbEtTU3FmcUxMRnZnREZRcDFhYnN4SjZEZDRqT1k5ZFBWLTZUcXhMOE1OSzB5U3ItX3NoQlExVlZpQUNMREJWeUpDNUltdlBhTk81WFhXdGJqOTVj?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veraxa Biotech AG (VRXA) Revenue Breakdown - Main Composition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5uQWVUd0xUaEVZMDU4aWw3WDN6a281RXFuSTBsYTFsM0J4aFRSUXQ1SnNIVnQtc2RKemtlNTdrOEI2R3gxLWE0M09yNld1UThNTk8zd3cyRTI5aVhGZjk4dUNMNXJzUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-13T09:21:59+00:00", "published_display": "13 Jun 2026 09:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pre-Market Movement | VRXA.US Stock Price Fluctuates Amid Multiple News Items", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQUkZLZ2hXcTNsQTZnMEVWODFtSTA2ajdvVDdjamRfWVpfR3E4WmtwRnk2cmM3TXFoeGN1bmE5dmhoTHdqNElZemxuZTR0N1lkTmRxdmllbjdDb1ZoM3lMWnV0WkZYN0FOSUNVWEdqRU00OGF5VWtYQTM0S1ZHcGUwWVZySFNUVldiV3pVMFVoU0FkSWlOZGlzV0xVVFRhWUpBd05hV3hPclVsd3UtdHc?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free cash flow per share of Veraxa Biotech AG \u2013 NASDAQ:VRXA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVGtnM3VaTElNRE01eUtENkRXbjFPQkNHWm15WkhIYllaUTExX2VCTDk4R0lqSGNia2NkTGdHWllWbnZmeFdKRk1PVGRKWko2OWYzazdkdnc1ZUVxSmxYSDhYVnNCVHh4MmM4Y0NwVmlValNPbjJYdXFYUXcyU2tjTnpiN0RyNVJvVk5tRUlMcW5VcGZyRWF5OWRuaWVnSUlNNEhmcDVVMDQ1UQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-12T18:56:52+00:00", "published_display": "12 Jun 2026 18:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veraxa Biotech AG Financial Statements \u2013 NASDAQ:VRXA", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE0zYVNYWWd0RnZnVWFVLVMwWmtfMk1BM0FZUTdnQnFPNm9GaTdFZUpZVGljWHE0OTBITVVXRHJiLUZWMXUzejhxR0p4djZKRk9hS1h2TEtvUmhFdFRrckJCWWNpcVQ1cGdrczNJV1Vianlva3RLVmw4?oc=5", "source_name": "TradingView", "published_at": "2026-06-12T15:35:25+00:00", "published_display": "12 Jun 2026 15:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (NASDAQ: VRXA) Completes Business Combination, Begins Trading on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxPOFhKblpOdXV5VnQzZUZCZ013dVQtbFBmRUtvUVc3a0RpOEw2V1pybjdoRDZ4dmk4UHVVcnN4STNBZVAzYmltUVc3ZXJWOGpnSEdSM3Rydy00WWJmNjBwQlhlQ2xPZzdwb1QyRndYQmV2RkVFR0s5N2xBSFE3TzM0NzlNcHVkRGIyV0tIakZNQTZWaDduWDAwMmFxVWRYeC05Tl9iVHQ3bmg4d1BacWs3SW5icEJSN3hzdUdhaUNJblViTS1ZRnpoNVd5QzUyZzFFbEo3YmZ1elJxc3VCUmxDRnV2VEdLcEFtc0steUROcERzRDVlLVE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Is 'One to Watch'", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNLXFkWk5nTjlRY2Z5cDMtYmNodjE4N3BiaXg3M0FUS3d4RmhRdUVVVTNDZmJMLXJvbUxLMUhOd2ctLWRWck1JTVdYYS1ZbGtlYVF6UmFOVjlpck9lNHliRmJ4UGZJVnVfNTJQaHpXeEY3Ymp5MG1WU3o2bFhaUWNFOUF5UmdpN1JvV0VNOWJ0QmFETm5qS3RKOW1McXQtTkU?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (NASDAQ: VRXA) Is \u2018One to Watch\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOMjdYTDA5RTlScmo3QzhmYkpLSEgta2tuVDJKLUxhYVJmQUI2WUNUT1ozcUFaXzRvdVNyOXlJTDgzanVKb21MTzNsQVBnbTdtM3FEYmtySEhwZFNVa3F4LTNvQkNqRXI0VzJCZDVyUFRiRWFCeFFPdmJNLTg0TUx0TW5tOHJfbVdEa3duSTZaaw?oc=5", "source_name": "Barchart.com", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAJBVV95cUxPWGFIWUFRSXkybkZxLWViZzdlZlFwUEhRSXVIajhSMndtaHowZC13MGxtUzhkRFY4WUxPRFRiYVc5LS1ITWlWSC1VZVJmOTFEMWVNYmtIRXlNZWp0UXpOaGl2Z3AzNkFHZkNvSmlYempXcUl1OEFVblc5alBmRllCM196ZkotTWs3NlpFSk04TWdpOTZNeTJ1cXBFeXIwcnc4WEhrbmRCZm9MX1Q3NnhUSVVDTGR2SFF1LXdmTUd1a1QtNnN2SmFBWDg0QlB5cGJnYUpVSkR5SERWcFFqS3FCMDlCOUIxVFZLUUdMaTVUY014aUkxQV9JaG1hSllGUHQtOWdQUk5oejRtQ1RzQkNlTDBwb3hiSF9qdklpdw?oc=5", "source_name": "NTB Kommunikasjon", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Acquisition Corp. (VACH) delists Class A shares, warrants, units from Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPME1jUWw4eExsNE5aYXpSS1UxMmRaN1M2MnRhaHpUTldMT29KY3N1UkVsTjNlVHhuWnVFRmg1d1ZmMnpZNXB3NjB6MkFlM2k1MU1vcFFaeDJpcnJXLXRPU3NqeVdwY0RBNkJuZUh4NzlWc1J6ekF0cjViUEc1MmJHSVBCbEdBcjJIWUlRQldjanlQRDlvV2RpeVhrNnZMOVNkMkJIRFVMd3dKUkZaNTZrWXNTQW52b0I2MnVJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOLVIxWXFKZGE5Zmg5MWpOTUtjY1kxTjBlclJmYmItRkJZOE93YTlCSGVuMk84WUdCSnVtenpoekdxYlhIMFVPZnliWV9jckM0ZHJfWG9kMTd4TDJoRW1GSzJwQnJRcmFPLVZXbjdqUm16OUZkWG1qMWZSU2dpSTJXMEw2YWNVTFVCYWU0eGl4MVE2SEx6Z2ZaMFFZNzBCd3lwT2dmNU50TzdyS2pjTDFRbFQweWZJSllzYmlxX0sya0dXWVdMS1E?oc=5", "source_name": "Reuters", "published_at": "2025-04-23T07:00:00+00:00", "published_display": "23 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/why-veraxa-biotech-vrxa-could-184016312.html", "source_name": "NewMediaWire", "published_at": "2026-07-15T18:40:16+00:00", "published_display": "15 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-vrxa-partners-ardigen-193000265.html", "source_name": "NewMediaWire", "published_at": "2026-07-13T19:30:00+00:00", "published_display": "13 Jul 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC\u00ae Pipeline", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-launch-ai-enabled-110000224.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI partnership aims to sharpen cancer target selection at VERAXA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVnl4ZzZGN3BtUXVxQlJ5a3ZDalg5c3FVWkQzc0U5MUpIcjRrMk1WVlE3eWI1MTctRDhnSnZ4WGxHS1dZeFo1NHp3dUFOOGV1c3ViSlBLWE9NR01tQ1hDVzVBc09zdkt2VzYtQjBOLWxLeXdaUE9wRnZTcnlRQVBsUTkwNHFxaTVhZ3hUNl81NXNmRTlLTVpueWF0LWtzdmJsQXNkM3B0TkJDYWctTkFfRFVtaUkxWGN0c0hF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech AG Appoints Carl von Halem as Interim\u00a0Chief Financial Officer and Successor to Torsten B\u00fcrgermeister", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-ag-appoints-carl-200500695.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T20:05:00+00:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Advances Lead BiTAC(R) T-Cell Engager Program With Cell Line Development Partnership", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-vrxa-advances-lead-183000631.html", "source_name": "NewMediaWire", "published_at": "2026-07-09T18:30:00+00:00", "published_display": "09 Jul 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRXA Price History for Veraxa Biotech Ag Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1ZaFN4bTZVd3phOGZwUUMwTUNNeWF5SVFpSlpDU3ozRlFvbVBrazJqT2FmaGgxQ2RzVWtlR0h2a0ZpVW00R2ZFUlpMM1ZGcnFSSFphSWZibUV6QV81X3hZT2hKZEh0SlFk?oc=5", "source_name": "Barchart.com", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9uMEF3NUMtNlltZ1gxR2xuMWZyMGRZYnpib3Q1NWo4VjFZMmM0WC1UVm9pWTNGSzJxNW12enVWSjFWR2FNU3pNRTM1RnNpQy1j?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T03:14:35+00:00", "published_display": "07 Jul 2026 03:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-vrxa-highlights-bitac-190000080.html", "source_name": "NewMediaWire", "published_at": "2026-07-06T19:00:00+00:00", "published_display": "06 Jul 2026 19:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxQbDhyTWhiZXZiVnVsd1FKM3dkU245MktZOHpwUFNCamRwQUtXQjlvSHNnbHh6MHFhSjZLdFdHWE1pVUo3Qm1XQlVjQ1hURy1kZHViR2I1bTBDWlE3dmJvcVZaSnA0QXp3TmFXQ19zck04V2pneFdzZlBScm93R2p5X3M4cTNvWnNpZ3RtMU5xSDhGd1NkUVloNFVCcFhkcjJVdFV0ZzZnc0R4UVROZHFmcmxESmhRX2g1V2t3azFMVXRjWXYtNFQxZno1SzFtRE1LRktjdTc0VEZzSFNqM2xGOC1CeEJNVFNxcmZNNVhQVXMtWUVPcW90enFfYldPbEhfb0pEWHdaVVptN2lVY0NtVjQ0bHhfcm9K?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-06T16:13:27+00:00", "published_display": "06 Jul 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Cancer Therapy Strategy VERAXA Is Betting the Company On", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cancer-therapy-strategy-veraxa-betting-160053349.html", "source_name": "Exec Edge", "published_at": "2026-07-06T16:00:53+00:00", "published_display": "06 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech Provides Business Update and Further Details on\u00a0Partnering Strategy and Development Timelines", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-provides-business-further-110000337.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T11:00:00+00:00", "published_display": "06 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA says its BiTAC cancer pipeline is drawing partner interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQRXc1WlFyekVveDdKSEhFNl96QlBUWnRxWlV5YlY0bHU4MGRPNXZuTUdJc1IzSGNXQ2QzdmhtM1VDQmFrWGJ6VEUtWjRyenI1c3FYN0kySzZSX1Y1V2pseGQyUmt0Zzg3YjhFdTVHY1VfNTljd3JZbUZGZXFVX0YxbE9nVkhmMXZYZURsc2ZsSmEwX2dNOUdEYmlpemNLS1I5TzlEaThPZUVnVk1sUlJKczRwZTFLbDFP?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veraxa Biotech Holding (VRXA) Stock Analysis Report | Financials & Insights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBSQi15YkhYZFNXOXN2RV9KMzVraFkyOTZTSlVudmJPa01OX25BTVNqVEpSdnlmTjNVT3RaRzNEU0w2SXd6b2lnT011M2JTNHJnMFhF?oc=5", "source_name": "Benzinga Espa\u00f1a", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/veraxa-biotech-vrxa-initiates-cell-193000059.html", "source_name": "NewMediaWire", "published_at": "2026-07-02T19:30:00+00:00", "published_display": "02 Jul 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOOTRONFI2QTZxVGRlbHRmeUpPUk0wY1k3U19iWmhwbm1vTC1hQkdTaTd0Rk1GdTZMZ1VkZVFEMDktWEQ5LUJNQk1vVXkzT1hoUG1VUEppMks1ZklGY3RPVWlmbUZoTjNLUFJ1T0VqbTVvbHlsZVdCY0gxRmhEOTFZS3pWX2dIeXZ1UGJFazNjWTU3Smk3LW5j?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA advances lead cancer drug toward manufacturing work with ATUM", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPaVlOeWFkVVVoRmxYdjk2LVJEUHA0eHRuM1VoWkFEaUFQTmdjek5DRXJUbTdiVzZjU01fWC1OdHZNZEhycUJfdFpTNng5SzdBcXp5bkRSYXczU0R4bFJubWhpbWRrMFQwSmZYM3g4aUtHOFdCV1YtSXZtSkREdzRLNmEweElaampFM1RmQWt2b0RiR3EzYzd2cEpjSnFiZXFVT19zempvRzFRMmcxOV9tVGJ1dklNZVd3cGFYNlBYVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA adds 60% more lab space in Heidelberg for cancer drug work", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcE9rckFtZE96T3VsU1JEcEk5bHVyWWhpa0tFcVZVbi0wODZDdExMWm5wS0FZVEFuMUpRUzYwWWJhNXpLNkQ5QURIVGlxc3NLaGRScWMxZGVpeHNqSmlhLXdqU1RvZV91N0ZDUmFYWWxId09lYW1WUnc0V3AzTnI2TzNmbzlMUzZ6aXhTOWNLZk5MTko3MUtma2VQWU5Ec0FDNl9ib1U2U1ppUzdLNjJ4LU1XVlJyLS1saVN5VTNNaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOSFVUR1lwVFdDbkhnT1M3RnZlSUcwUzA1T0kyUldmTThDZVlmUlV0NVExLXpHM3IwVUV3eHZGSnB0bk9pNkxyTl9HSThOdl9uMF9nYzh3RU1Pb2xHYW9IeDQ2bFRqVnJuTE9IREZuMVFFeGlseGJTcGtJR1FOTVp0VldRZ3NyTVdMWFhqQ0g1bEZyUlVLbkZjWDdzeFpnX3hsRkFDQTRKN3FvUmVhdTN2UjBURjUxRDJFZzhqN2sxcjVCMEdKcUg2cUtIaWxWZEwwbHVKLWhEN3k?oc=5", "source_name": "Barchart.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRXA SEC Filings - Veraxa Biotech AG 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE10UnllaUM0VzdKQVRCWmRja3hKTjRtaGdkRHlJT0MtdlpQSE5WVU9CVVRVcldpbUZmVVhBZ0RwZ3VkOFM3UGtRX2RvX2RrZFN4aXViQ2xNUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veraxa Biotech Stock: Post-Merger Valuation Does Not Match The Risk (NASDAQ:VRXA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOUzdVbFdoUWtGZkNMMFgtRlZ2VDJIZWdaMEd0WjZ1V0xJMUxUd0ZFRmNEQkt2SVh3RkgxQ2NGTHFKNUtKTFlfYk9aYXJLbDdWbEtTU3FmcUxMRnZnREZRcDFhYnN4SjZEZDRqT1k5ZFBWLTZUcXhMOE1OSzB5U3ItX3NoQlExVlZpQUNMREJWeUpDNUltdlBhTk81WFhXdGJqOTVj?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veraxa Biotech AG (VRXA) Revenue Breakdown - Main Composition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5uQWVUd0xUaEVZMDU4aWw3WDN6a281RXFuSTBsYTFsM0J4aFRSUXQ1SnNIVnQtc2RKemtlNTdrOEI2R3gxLWE0M09yNld1UThNTk8zd3cyRTI5aVhGZjk4dUNMNXJzUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-13T09:21:59+00:00", "published_display": "13 Jun 2026 09:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pre-Market Movement | VRXA.US Stock Price Fluctuates Amid Multiple News Items", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQUkZLZ2hXcTNsQTZnMEVWODFtSTA2ajdvVDdjamRfWVpfR3E4WmtwRnk2cmM3TXFoeGN1bmE5dmhoTHdqNElZemxuZTR0N1lkTmRxdmllbjdDb1ZoM3lMWnV0WkZYN0FOSUNVWEdqRU00OGF5VWtYQTM0S1ZHcGUwWVZySFNUVldiV3pVMFVoU0FkSWlOZGlzV0xVVFRhWUpBd05hV3hPclVsd3UtdHc?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free cash flow per share of Veraxa Biotech AG \u2013 NASDAQ:VRXA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVGtnM3VaTElNRE01eUtENkRXbjFPQkNHWm15WkhIYllaUTExX2VCTDk4R0lqSGNia2NkTGdHWllWbnZmeFdKRk1PVGRKWko2OWYzazdkdnc1ZUVxSmxYSDhYVnNCVHh4MmM4Y0NwVmlValNPbjJYdXFYUXcyU2tjTnpiN0RyNVJvVk5tRUlMcW5VcGZyRWF5OWRuaWVnSUlNNEhmcDVVMDQ1UQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-12T18:56:52+00:00", "published_display": "12 Jun 2026 18:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veraxa Biotech AG Financial Statements \u2013 NASDAQ:VRXA", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE0zYVNYWWd0RnZnVWFVLVMwWmtfMk1BM0FZUTdnQnFPNm9GaTdFZUpZVGljWHE0OTBITVVXRHJiLUZWMXUzejhxR0p4djZKRk9hS1h2TEtvUmhFdFRrckJCWWNpcVQ1cGdrczNJV1Vianlva3RLVmw4?oc=5", "source_name": "TradingView", "published_at": "2026-06-12T15:35:25+00:00", "published_display": "12 Jun 2026 15:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (NASDAQ: VRXA) Completes Business Combination, Begins Trading on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxPOFhKblpOdXV5VnQzZUZCZ013dVQtbFBmRUtvUVc3a0RpOEw2V1pybjdoRDZ4dmk4UHVVcnN4STNBZVAzYmltUVc3ZXJWOGpnSEdSM3Rydy00WWJmNjBwQlhlQ2xPZzdwb1QyRndYQmV2RkVFR0s5N2xBSFE3TzM0NzlNcHVkRGIyV0tIakZNQTZWaDduWDAwMmFxVWRYeC05Tl9iVHQ3bmg4d1BacWs3SW5icEJSN3hzdUdhaUNJblViTS1ZRnpoNVd5QzUyZzFFbEo3YmZ1elJxc3VCUmxDRnV2VEdLcEFtc0steUROcERzRDVlLVE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (VRXA) Is 'One to Watch'", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNLXFkWk5nTjlRY2Z5cDMtYmNodjE4N3BiaXg3M0FUS3d4RmhRdUVVVTNDZmJMLXJvbUxLMUhOd2ctLWRWck1JTVdYYS1ZbGtlYVF6UmFOVjlpck9lNHliRmJ4UGZJVnVfNTJQaHpXeEY3Ymp5MG1WU3o2bFhaUWNFOUF5UmdpN1JvV0VNOWJ0QmFETm5qS3RKOW1McXQtTkU?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech (NASDAQ: VRXA) Is \u2018One to Watch\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOMjdYTDA5RTlScmo3QzhmYkpLSEgta2tuVDJKLUxhYVJmQUI2WUNUT1ozcUFaXzRvdVNyOXlJTDgzanVKb21MTzNsQVBnbTdtM3FEYmtySEhwZFNVa3F4LTNvQkNqRXI0VzJCZDVyUFRiRWFCeFFPdmJNLTg0TUx0TW5tOHJfbVdEa3duSTZaaw?oc=5", "source_name": "Barchart.com", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAJBVV95cUxPWGFIWUFRSXkybkZxLWViZzdlZlFwUEhRSXVIajhSMndtaHowZC13MGxtUzhkRFY4WUxPRFRiYVc5LS1ITWlWSC1VZVJmOTFEMWVNYmtIRXlNZWp0UXpOaGl2Z3AzNkFHZkNvSmlYempXcUl1OEFVblc5alBmRllCM196ZkotTWs3NlpFSk04TWdpOTZNeTJ1cXBFeXIwcnc4WEhrbmRCZm9MX1Q3NnhUSVVDTGR2SFF1LXdmTUd1a1QtNnN2SmFBWDg0QlB5cGJnYUpVSkR5SERWcFFqS3FCMDlCOUIxVFZLUUdMaTVUY014aUkxQV9JaG1hSllGUHQtOWdQUk5oejRtQ1RzQkNlTDBwb3hiSF9qdklpdw?oc=5", "source_name": "NTB Kommunikasjon", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Voyager Acquisition Corp. (VACH) delists Class A shares, warrants, units from Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPME1jUWw4eExsNE5aYXpSS1UxMmRaN1M2MnRhaHpUTldMT29KY3N1UkVsTjNlVHhuWnVFRmg1d1ZmMnpZNXB3NjB6MkFlM2k1MU1vcFFaeDJpcnJXLXRPU3NqeVdwY0RBNkJuZUh4NzlWc1J6ekF0cjViUEc1MmJHSVBCbEdBcjJIWUlRQldjanlQRDlvV2RpeVhrNnZMOVNkMkJIRFVMd3dKUkZaNTZrWXNTQW52b0I2MnVJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOLVIxWXFKZGE5Zmg5MWpOTUtjY1kxTjBlclJmYmItRkJZOE93YTlCSGVuMk84WUdCSnVtenpoekdxYlhIMFVPZnliWV9jckM0ZHJfWG9kMTd4TDJoRW1GSzJwQnJRcmFPLVZXbjdqUm16OUZkWG1qMWZSU2dpSTJXMEw2YWNVTFVCYWU0eGl4MVE2SEx6Z2ZaMFFZNzBCd3lwT2dmNU50TzdyS2pjTDFRbFQweWZJSllzYmlxX0sya0dXWVdMS1E?oc=5", "source_name": "Reuters", "published_at": "2025-04-23T07:00:00+00:00", "published_display": "23 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 75, "total_relevant": 40, "sentiment_summary": {"positive": 2, "negative": 1, "neutral": 37, "score": 50, "total": 40, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "deals", "label": "Deals and strategy", "weight": 2.9, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 2, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 2.2, "latest_week": "2026-07-10", "one_week_move": 7.8, "four_week_move": -89.0, "twelve_week_move": null, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -64.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 0.0, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.8% over one week, -89.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "NewMediaWire", "count": 5}, {"label": "GlobeNewswire", "count": 3}, {"label": "Barchart.com", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "The Globe and Mail", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 32}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 9}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "32", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.8% over one week, -89.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D"}], "updated_at": "2026-07-16T01:32:33.722279+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}